← Leaderboards
Jianguo Tao
H. Lee Moffitt Cancer Ctr & Res Inst
$3,452,402
Attributed
$4,898,873
Total exposure
6
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2009–20$2M$1.5M$1M$500K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$4,898,873 · 6
By mechanism
R01$4,674,413 · 5
R21$224,460 · 1
Top collaborators
- Eduardo M Sotomayor5 shared
- John L. Cleveland1 shared
- Jun Qi1 shared
Most similar at H. Lee Moffitt Cancer Ctr & Res Inst
Same institution · by research overlap
- John L. Cleveland$27,832,236
- Kenneth Lynn Wright$8,797,565
- Derek Ronald Duckett$9,922,620
Others in their field
Top investigators on “In Vivo”
- David Heimbrook · Leidos Biomedical Research, Inc.$371,850,582
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Dennis R. Burton · Scripps Research Institute$212,708,174
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$98,374,200
Research focus
In VivoCellsResponseLymphomaSamplingCell LineBiologyDrug ResistanceBaseSignal TransductionGeneticMediatingApoptosisPlayB-Cell Nonhodgkins LymphomaPublic Health RelevanceSignal PathwayInhibitor/AntagonistCell Cycle ArrestFamilyB Lymphoid MalignancyMolecularAdhesionsResistance
Grant awards (14)
New Therapeutic Vulnerabilities for Aggressive B-Cell Lymphoma$554,729
R01 · FY2020 · CA · contact PI
Transcriptional and Epigenetic Adaptation as Novel Therapeutic Vulnerabilities for Mantle Cell Lymphoma$513,372
R01 · FY2020 · CA · contact PI
Role of Specific Histone Deacetylases in Lymphoma Immunobiology and Therapy$351,691
R01 · FY2019 · CA
Epigenetic Regulation of Drug Resistance to ABT-199 in B-cell Malignancies$224,460
R21 · FY2019 · CA · contact PI
Role of Specific Histone Deacetylases in Lymphoma Immunobiology and Therapy$362,569
R01 · FY2018 · CA
Role of Specific Histone Deacetylases in Lymphoma Immunobiology and Therapy$362,569
R01 · FY2017 · CA
Role of Specific Histone Deacetylases in Lymphoma Immunobiology and Therapy$362,569
R01 · FY2016 · CA
Role of Specific Histone Deacetylases in Lymphoma Immunobiology and Therapy$385,444
R01 · FY2015 · CA
Targeting Negative Regulatory Pathways for Immunotherapy of B-Cell Lymphomas$437,284
R01 · FY2014 · CA · contact PI
Tageting BAFF and BAFF-Induced Non-Canonical NF-kB Pathways for Enhancing Mantle$252,770
R01 · FY2013 · CA · contact PI
Tageting BAFF and BAFF-Induced Non-Canonical NF-kB Pathways for Enhancing Mantle$268,903
R01 · FY2012 · CA · contact PI
Tageting BAFF and BAFF-Induced Non-Canonical NF-kB Pathways for Enhancing Mantle$268,903
R01 · FY2011 · CA · contact PI
Tageting BAFF and BAFF-Induced Non-Canonical NF-kB Pathways for Enhancing Mantle$277,220
R01 · FY2010 · CA · contact PI
Tageting BAFF and BAFF-Induced Non-Canonical NF-kB Pathways for Enhancing Mantle$276,390
R01 · FY2009 · CA · contact PI